论文部分内容阅读
目的探讨 p5 3和p2 1在骨巨细胞瘤 (GCT )的表达及其与GCT病理分级和复发的关系。方法应用SP免疫组织化学方法检测 p5 3和p2 1在5 2例GCT(按Jaffe分级 :Ⅰ级 15例、Ⅱ级 2 5例、Ⅲ级 12例 )中的表达。结果14例 p5 3表达阳性 ,阳性率 2 6.9% ;7例 p2 1表达呈阳性 ,阳性率13 .5 %。其阳性表达与病理分级均差异无显著性 (P值分别为 0 .699;0 .65 8,P >0 .0 5 )。p5 3和 p2 1在复发和无复发的病例中 ,阳性表达率分别为 46.2 %、2 0 .5 %和 2 3 .1%、10 .3 %。两者同时阳性表达的有 2例 ,p5 3和p2 1同时过表达与GCT复发差异有显著性 (P =0 .0 42 )。结论p5 3和 p2 1在GCT中的表达与病理分级无关而与其复发有关。
Objective To investigate the expression of p53 and p21 in giant cell tumor of bone (GCT) and its relationship with pathological grade and recurrence of GCT. Methods SP immunohistochemistry was used to detect the expression of p53 and p21 in 52 cases of GCT (15 cases in grade I, 25 cases in grade II, and 12 cases in grade III according to Jaffe classification). Results The expression of p53 was positive in 14 cases, the positive rate was 26.9%. The expression of p21 was positive in 7 cases, the positive rate was 13.5%. There was no significant difference between positive expression and pathological grade (P values were 0.699; 0.65, P > 0.05). The positive expression rates of p53 and p21 in relapsed and relapsed cases were 46.2%, 20.5%, 2.3%, and 10.3%, respectively. There were two cases of positive expression of both, and there was a significant difference between the simultaneous expression of p53 and p21 (P = 0.042) and GCT recurrence. CONCLUSIONS The expression of p53 and p21 in GCT was not related to pathological grade but related to its recurrence.